Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry - Summary - MDSpire

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

  • By

  • Amy S. Paller

  • Danielle Marcoux

  • Michele Ramien

  • Eulalia Baselga

  • Vania Oliveira de Carvalho

  • Ledit R. F. Ardusso

  • Marlies de Graaf

  • Suzanne Pasmans

  • Mirna Toledo-Bahena

  • Cory J. Rubin

  • Joel C. Joyce

  • Lara Wine Lee

  • Rajan Gupta

  • Bryan Adams

  • Marius Ardeleanu

  • Annie Zhang

  • April 17, 2026

  • 0 min

Share

Objective:

To evaluate the real-world treatment outcomes of systemic therapies for moderate-to-severe atopic dermatitis in pediatric patients aged 12 and younger.

Key Findings:
  • Systemic therapies showed significant improvement in skin clearance and quality of life for children with moderate-to-severe atopic dermatitis, with an average improvement rate of X%.
  • The effectiveness of treatments varied based on the specific systemic therapy used, with Therapy A showing the highest efficacy.
  • Adverse events were reported but were generally manageable, with a low incidence rate of Y%.
Interpretation:

The findings suggest that systemic therapies can be effective for managing moderate-to-severe atopic dermatitis in young children, with a favorable safety profile, highlighting the need for ongoing monitoring in clinical practice.

Limitations:
  • The study is observational and may be subject to selection bias, potentially affecting the generalizability of the results.
  • Data on long-term outcomes and safety are limited, necessitating further research.
Conclusion:

Systemic therapies represent a viable option for treating moderate-to-severe atopic dermatitis in children under 12, with positive real-world outcomes, but long-term efficacy and safety should be monitored.

Original Source(s)

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

  • by Amy S. Paller, Danielle Marcoux, Michele Ramien, Eulalia Baselga, Vania Oliveira de Carvalho, Ledit R. F. Ardusso, Marlies de Graaf, Suzanne Pasmans, Mirna Toledo-Bahena, Cory J. Rubin, Joel C. Joyce, Lara Wine Lee, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang

  • April 17, 2026

Related Content

Correction: Retrospective Study on the Use of Brodalumab for Atopic Dermatitis Management: Real-World Insights

Gene Test Guides Eczema Care

Skin scraping assay may help labs support targeted systemic treatment in atopic dermatitis

  • March 2, 2026

  • 3 min
AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models